Infectious Disease / Microbiology Updates
6.65K subscribers
31 photos
3 videos
23 files
3.73K links
All the atest articles, research and news from worlds leading Infectious Disease Journals.

Discussion group
https://t.me/Professional_Medical_Discussion
Download Telegram
[Profile] Katie Anders—improving global dengue control
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00012-5/fulltext?rss=yes

Katherine (Katie) Anders grew up in an academic home in Melbourne, VIC, Australia with a malariologist father and an immunologist mother. “Discussions about human biology and disease, health inequities, and advances in medical science were standard meal-time conversations at our house: it was subliminal exposure to a scientific way of thinking from an early age”, Anders told The Lancet Infectious Diseases. And while she initially resisted an academic career path, an interest in medicine and science was always there.
[Newsdesk] CDC cuts to childhood vaccine recommendations
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00014-9/fulltext?rss=yes

New childhood vaccine recommendations from the US Centers for Disease Control and Prevention have been widely criticised by experts. Priya Venkatesan reports.
[Newsdesk] Brazil approves domestic single-shot dengue vaccine
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(26)00013-7/fulltext?rss=yes

In December 2025, the domestically produced Butantan-DV vaccine was approved by Brazil's regulatory agency for use in individuals aged 12–59 years. Marcia Triunfol reports.
[Comment] Lessons from Brazil's elimination of vertical HIV transmission
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(26)00002-0/fulltext?rss=yes

In 2025, WHO's validation of Brazil for the elimination of vertical transmission of HIV (sometimes referred to as mother-to-child transmission of HIV) is a landmark global public health achievement.1 As the most populous country to reach this milestone, Brazil shows that elimination is feasible even in large, socially diverse, and unequal settings when political commitment, universal health coverage, and human rights are placed at the centre of health policy.1 This success highlights the urgency for countries in sub-Saharan Africa to implement concrete, scalable, and equity-oriented strategies to achieve similar progress in eliminating vertical transmission of HIV.
[Articles] Acceptability and tolerability of long-acting injectable cabotegravir–rilpivirine in adolescents with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multicentre, open-label, non-comparative phase 1/2 trial
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(25)00241-3/fulltext?rss=yes

Acceptability and tolerability of intramuscular cabotegravir–rilpivirine remained high through to 48 weeks of treatment, suggesting that this long-acting intramuscular treatment approach is well received by diverse populations of adolescents with HIV across multiple settings.
2
[Articles] Safety, antiviral activity, and pharmacokinetics of long-acting injectable cabotegravir–rilpivirine in virologically suppressed adolescents living with HIV-1 (IMPAACT 2017/MOCHA): 48-week results of a multinational, phase 1/2, single-arm study
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(25)00242-5/fulltext?rss=yes

Week 48 data from the first virologically suppressed adolescents with HIV-1 who switched from daily oral to intramuscular cabotegravir and intramuscular rilpivirine every 8 weeks showed favourable safety, pharmacokinetics, and virological suppression informing both real-world use, where approved, and ongoing regulatory submissions, where approval is pending.